Horizon Kinetics’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Horizon Kinetics’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$282K	Hold	67,200	–	–	0.01%	399
2018 Q3	$421K	Hold	67,200	–	–	0.01%	313
2018 Q2	$540K	Hold	67,200	–	–	0.01%	257
2018 Q1	$501K	Hold	67,200	–	–	0.01%	269
2017 Q4	$400K	Hold	67,200	–	–	0.01%	375
2017 Q3	$495K	Sell	67,200 -60	-0.1%	-$381	0.01%	270
2017 Q2	$456K	Hold	67,260	–	–	0.01%	298
2017 Q1	$635K	Buy	67,260 +60	+0.1%	+$599	0.02%	248
2016 Q4	$581K	Hold	67,200	–	–	0.02%	260
2016 Q3	$425K	Hold	67,200	–	–	0.01%	340
2016 Q2	$284K	Hold	67,200	–	–	0.01%	465
2016 Q1	$293K	Hold	67,200	–	–	0.01%	460
2015 Q4	$412K	Hold	67,200	–	–	0.01%	415
2015 Q3	$384K	Hold	67,200	–	–	0.01%	416
2015 Q2	$501K	Hold	67,200	–	–	0.01%	402
2015 Q1	$402K	Hold	67,200	–	–	0.01%	427
2014 Q4	$508K	Hold	67,200	–	–	0.01%	408
2014 Q3	$349K	Hold	67,200	–	–	﹤0.01%	443
2014 Q2	$290K	Hold	67,200	–	–	﹤0.01%	463
2014 Q1	$275K	Hold	67,200	–	–	﹤0.01%	470
2013 Q4	$358K	Hold	67,200	–	–	﹤0.01%	452
2013 Q3	$337K	Hold	67,200	–	–	﹤0.01%	406
2013 Q2	$300K	Buy	+67,200	New	+$302K	﹤0.01%	370

Other funds holding PGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Horizon Kinetics's PGNX Position: Q4 2018 in Review

Horizon Kinetics held its Progenics Pharmaceuticals Inc (PGNX) position steady in Q4 2018 at 67,200 shares worth $282K. The position accounts for 0.01% of the portfolio, ranked #399.

Horizon Kinetics first reported a position in PGNX in Q2 2013 and has held it in 23 quarters since. The position peaked at $635K in Q1 2017. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

Horizon Kinetics held 67,200 shares of Progenics Pharmaceuticals Inc worth $282K as of Q4 2018.
Horizon Kinetics left its Progenics Pharmaceuticals Inc share count unchanged in Q4 2018.
Progenics Pharmaceuticals Inc made up 0.01% of Horizon Kinetics's portfolio in Q4 2018, its #399 holding.
Horizon Kinetics first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and has held it in 23 quarters since.
Horizon Kinetics's Progenics Pharmaceuticals Inc position peaked at $635K in Q1 2017.
150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Horizon Kinetics's 13F filing for Q4 2018, filed 14 Feb 2019.